Colin J. Daniel

Colin J. Daniel

Auto-generated profile, based on publicly available information

Colin J. Daniel

Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2025 in Cancer Research
Verified
Journal Article
Closed access
CBChloe L. Bowman
Chloe L. Bowman
CDColin J. Daniel
Colin J. Daniel
ECEric J. Carlson
Eric J. Carlson
VSVidhi M Shah
Vidhi M Shah
AFAmy S. Farrell
Amy S. Farrell
ELEllen M. Langer
Ellen M. Langer
The prolyl isomerase PIN1 is overexpressed in cancer and contributes to cancer cell–intrinsic phenotypes, including proliferation and migration. However, PIN1 may also function in stromal cells within the tumor microenvironment. In this study, we showed that PIN1 is a critical regulator of pancreatic stellate cell (PSC) state at baseline and in response to the myofibroblast-activating factor TGFβ. Loss or inhibition of PIN1 altered the epigenetic and transcriptional responses of PSCs to TGFβ, preventing PSC differentiation to a myofibroblast state and altering expression of secreted matrix proteins and signaling molecules. Consistent with inhibition of the TGFβ response, low fibroblast PIN1 expression in mouse and human pancreatic ductal adenocarcinoma correlated with low expression of αSMA, a marker of myofibroblast activation. Decreased PIN1 expression at baseline also altered paracrine hepatocyte growth factor (HGF) signaling from fibroblasts to tumor cells. PSCs with low PIN1 expression displayed reduced expression and secretion of HGF, resulting in an attenuation of c-MET receptor phosphorylation and signaling in nearby cancer cells. In allograft models, host PIN1 was critical for normal growth of a subset of pancreatic cancer cell lines that are responsive to HGF signaling. Through the identification of changes to fibroblast activation state and cross-talk following PIN1 loss or inhibition, these data suggest that systemic targeting of PIN1 will suppress the protumorigenic pancreatic ductal adenocarcinoma microenvironment and may differentially affect heterogeneous patient populations. Significance: PIN1 plays a critical role in the response of pancreatic stellate cells to TGFβ and can be targeted to attenuate myofibroblast activation and protumor cross-talk to suppress pancreatic cancer progression.

1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
KPKatherine R. Pelz
Katherine R. Pelz
PJPhilip Jimenez
Philip Jimenez
CDColin J. Daniel
Colin J. Daniel
SNSamuel D. Newton
Samuel D. Newton
MCMelissa Cunningham
Melissa Cunningham
TZTeresa A. Zimmers
Teresa A. Zimmers
Preclinical models of pancreatic ductal adenocarcinoma (PDAC) can greatly benefit from noninvasive imaging for evaluating disease progression and therapeutic response. Imaging approaches that can accurately and simultaneously track primary tumor growth, metastatic dissemination, and host cachexia over time are lacking. Herein, we report an optimized dual-contrast microCT protocol for longitudinal imaging in orthotopic murine models of PDAC. This method enables high-resolution, volumetric quantification of orthotopic primary tumors, liver and lung metastases, and paraspinal skeletal muscle, providing a dynamic view of both the tumor and host physiology. MicroCT primary tumor measurements were strongly correlated with endpoint tumor weights and outperformed 2D ultrasound in early detection and volumetric accuracy, particularly for small or irregularly shaped tumors. This platform revealed heterogeneous metastatic kinetics across PDAC models and uncovered an early, heterogeneous onset of skeletal muscle wasting, a hallmark of cancer cachexia. Notably, this protocol mimics clinical CT surveillance by enabling opportunistic cachexia assessment from tumor imaging datasets and offers substantial advantages over destructive endpoint analyses. Furthermore, microCT radiation dose had no effect on model endpoints. By capturing the temporal dynamics of tumor progression and host response, dual-contrast microCT serves as a powerful translational platform for preclinical PDAC research and therapeutic testing. Significance: Dual-contrast microCT provides high-resolution, whole-body, noninvasive imaging in orthotopic murine PDAC models, enabling simultaneous tracking of tumor growth, metastasis, and skeletal muscle wasting, offering a clinically relevant, translational imaging platform.

15 May 2026 in Genes & Development
Verified
Journal Article
Open access
GCGabriel M. Cohn
Gabriel M. Cohn
CDColin J. Daniel
Colin J. Daniel
JEJennifer R. Eng
Jennifer R. Eng
AMAlannah S. MacDonald
Alannah S. MacDonald
JSJonathan St-Germain
Jonathan St-Germain
RSRosalie C. Sears
Rosalie C. Sears
Genomic instability is a hallmark of cancer, driving oncogenic mutations that enhance tumor aggressiveness and drug resistance. MYC, a master transcription factor that is deregulated in nearly all human tumors, paradoxically induces replication stress and associated DNA damage while also increasing expression of DNA repair factors and mediating resistance to DNA-damaging therapies. Emerging evidence supports a nontranscriptional role for MYC in preserving genomic integrity at sites of active transcription and protecting stalled replication forks under stress. Understanding how MYC's genotoxic and genoprotective functions diverge may reveal new therapeutic strategies for MYC-driven cancers. Here, we identify a noncanonical role of MYC in DNA damage response (DDR) through its association with DNA breaks. We show that phosphorylation at serine 62 (pS62-MYC) is crucial for the efficient recruitment of MYC to damage sites, its interaction with repair factors BRCA1 and RAD51, and effective DNA repair to support cell survival under stress. Proteomic profiling of the MYC interactome confirms a conserved interaction with components of the DDR pathway. These findings establish pS62-MYC as a key regulator of genomic stability and a potential therapeutic target in cancers.

3 November 2026
Verified
Other
Open access
YGYifei Guo
Yifei Guo
JFJennifer M. Finan
Jennifer M. Finan
ABAlexandra Bartlett
Alexandra Bartlett
KPKatherine R. Pelz
Katherine R. Pelz
SSShamilene Sivagnanam
Shamilene Sivagnanam
RERobert Eil
Robert Eil
Antibody information for flow cytometry staining

3 November 2026
Verified
Other
Open access
YGYifei Guo
Yifei Guo
JFJennifer M. Finan
Jennifer M. Finan
ABAlexandra Bartlett
Alexandra Bartlett
KPKatherine R. Pelz
Katherine R. Pelz
SSShamilene Sivagnanam
Shamilene Sivagnanam
RERobert Eil
Robert Eil
Antibody information for mIHC staining

15 December 2025
Verified
Other
Open access
CBChloe L. Bowman
Chloe L. Bowman
CDColin J. Daniel
Colin J. Daniel
ECEric J. Carlson
Eric J. Carlson
VSVidhi M Shah
Vidhi M Shah
AFAmy S. Farrell
Amy S. Farrell
ELEllen M. Langer
Ellen M. Langer
KPC cell lines show differential growth response to HGF treatment